Molecular Testing Improves Nodular Fasciitis Diagnosis - Top-Institutions - MDSpire

Molecular Testing Improves Nodular Fasciitis Diagnosis

USP6 analysis helps resolve uncertainty in atypical soft-tissue lesions

  • By

  • Andrea Surnit

  • April 3, 2026

  • 3 min

Share

Top Institutions in Pathology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Molecular Pathology
    • Soft Tissue Oncology
    • Cancer Genomics

  • #2

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Molecular Diagnostics
    • Soft Tissue Sarcoma
    • Oncologic Pathology

  • #3

    Brigham and Women's Hospital / Dana-Farber Cancer Institute
    Brigham and Women's Hospital / Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Molecular Pathology
    • Soft Tissue Tumors
    • Cancer Genomics

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Molecular Pathology
    • Soft Tissue Oncology
    • Genomic Medicine

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Molecular Diagnostics
    • Soft Tissue Tumors
    • Cancer Genomics

Original Source(s)

Molecular Testing Improves Nodular Fasciitis Diagnosis

  • by Andrea Surnit

  • April 3, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Neoadjuvant Chemo Did Not Improve Disease-Free Survival

Phase 3 NeoCol trial adds to mixed evidence as field shifts toward biomarker-guided approaches